Literature DB >> 21455248

Rheumatoid arthritis: International disparities in access to anti-TNF therapy.

Paul Emery1.   

Abstract

The establishment of new benchmarks for treatment outcomes promises to drive great advances in rheumatoid arthritis therapy, but data on ‘real life’ experience with biologic therapy demonstrate that geographic location influences the stage of disease at which these agents are initiated.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21455248     DOI： 10.1038/nrrheum.2011.27

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  10 in total

1.  Guidelines for initiation of anti-tumour necrosis factor therapy in rheumatoid arthritis: similarities and differences across Europe.

Authors:  P Emery; R Van Vollenhoven; M Ostergaard; E Choy; B Combe; W Graninger; K Krueger; M Matucci-Cerinic; F Navarro; P van Riel; L Settas; S Steinfeld
Journal:  Ann Rheum Dis       Date:  2009-04       Impact factor: 19.103

2.  The Dunlop-Dottridge Lecture: prognosis in inflammatory arthritis: the value of HLA genotyping and the oncological analogy.

Authors:  P Emery
Journal:  J Rheumatol       Date:  1997-07       Impact factor: 4.666

3.  Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial.

Authors:  Yvonne P M Goekoop-Ruiterman; Jeska K de Vries-Bouwstra; Cornelia F Allaart; Derkjen van Zeben; Pit J S M Kerstens; J Mieke W Hazes; Aelko H Zwinderman; André J Peeters; Johanna M de Jonge-Bok; Constant Mallée; Wim M de Beus; Peter B J de Sonnaville; Jacques A P M Ewals; Ferdinand C Breedveld; Ben A C Dijkmans
Journal:  Ann Intern Med       Date:  2007-03-20       Impact factor: 25.391

4.  Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD therapy.

Authors:  Philip G Conaghan; Elizabeth M A Hensor; Anne-Maree Keenan; Ann W Morgan; Paul Emery
Journal:  Rheumatology (Oxford)       Date:  2010-06-11       Impact factor: 7.580

5.  Patients with RA in remission on TNF blockers: when and in whom can TNF blocker therapy be stopped?

Authors:  Benazir Saleem; Helen Keen; Vincent Goeb; Rekha Parmar; Sharmin Nizam; Elizabeth M A Hensor; Sarah M Churchman; Mark Quinn; Richard Wakefield; Philip G Conaghan; Frederique Ponchel; Paul Emery
Journal:  Ann Rheum Dis       Date:  2010-04-26       Impact factor: 19.103

6.  Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial.

Authors:  R F van Vollenhoven; S Ernestam; P Geborek; I F Petersson; L Cöster; E Waltbrand; A Zickert; J Theander; A Thörner; H Hellström; A Teleman; C Dackhammar; F Akre; K Forslind; L Ljung; R Oding; A Chatzidionysiou; M Wörnert; J Bratt
Journal:  Lancet       Date:  2009-08-08       Impact factor: 79.321

7.  Comparison of anti-TNF treatment initiation in rheumatoid arthritis databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy.

Authors:  Chris Pease; Janet E Pope; Don Truong; Claire Bombardier; Jessica Widdifield; J Carter Thorne; Boulos Paul Haraoui; Eliofotisti Psaradellis; John Sampalis; Ashley Bonner
Journal:  Semin Arthritis Rheum       Date:  2010-12-17       Impact factor: 5.532

8.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

Authors:  Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green
Journal:  Arthritis Rheum       Date:  2006-01

9.  Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial.

Authors:  Paul Emery; Ferdinand C Breedveld; Stephen Hall; Patrick Durez; David J Chang; Deborah Robertson; Amitabh Singh; Ronald D Pedersen; Andrew S Koenig; Bruce Freundlich
Journal:  Lancet       Date:  2008-07-16       Impact factor: 79.321

10.  Treating rheumatoid arthritis to target: recommendations of an international task force.

Authors:  Josef S Smolen; Daniel Aletaha; Johannes W J Bijlsma; Ferdinand C Breedveld; Dimitrios Boumpas; Gerd Burmester; Bernard Combe; Maurizio Cutolo; Maarten de Wit; Maxime Dougados; Paul Emery; Alan Gibofsky; Juan Jesus Gomez-Reino; Boulos Haraoui; Joachim Kalden; Edward C Keystone; Tore K Kvien; Iain McInnes; Emilio Martin-Mola; Carlomaurizio Montecucco; Monika Schoels; Désirée van der Heijde; Desirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2010-03-09       Impact factor: 19.103
  10 in total
  1 in total

1.  Rheumatoid hand surgery: is there a decline? A 22-year population-based study.

Authors:  Rajiv Gogna; Graham Cheung; Melanie Arundell; Chris Deighton; Tommy R Lindau
Journal:  Hand (N Y)       Date:  2015-06
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.